Increasing evidence shows an interaction between olaparib-induced DNA damage and the immune system: PARPi release DNA fragments, neoantigens which make tumor cells more immunogenic and more sensitive to anti-PDL-1/PD-1 immunotherapy [156,159]. Here, CD274 is linked to neoplasm.